Clinical Characteristics and Prognostic Analysis of 24 Cases with Breast Diffuse Large B-cell Lymphoma

Abstract

Abstract Aim: We collected and analyzed the clinical characteristics and treatment methods of breast diffuse large B-cell lymphoma (B-DLBCL), and analyzed its prognosis to find the best treatment plan for B-DLBCL. Methods: We collected clinical data of 24 patients with B-DLBCL treated at Zhejiang Cancer Hospital between July 2003 and November 2014, and performed prognostic analysis according to the patients' pathological types and treatments, as well as plotting the Progression-free survival (PFS) and overall survival (OS) curves. Results: The included patients were all female (100%), with 92% (22/24) of patients presenting with breast masses, the majority (58%) presenting with left breast masses, and a very small portion presenting with bilateral breast masses; After a median follow-up of 51 (5-123) months, the PFS and OS of 24 patients were 72% and 80%, respectively; Among them, there were 14 cases of primary breast diffuse large B-cell lymphoma (PB-DLBCL), with corresponding PFS and OS of 85% and 83%, and their prognosis level is higher than that of secondary breast diffuse large B-cell lymphoma(SB-DLBCL); Among them, 13 patients underwent surgical treatment, and the prognosis of non-surgical patients was worse than that of surgical patients (PFS: 61% vs 80%; OS: 70% vs 87%); The 11 patients on rituximab had a non-significant improvement in PFS and OS compared with those not on rituximab (PFS: 72% vs 73%; OS: 79% vs 83%). Conclusion: B-DLBCL is a group of heterogeneous diseases. In our retrospective study, we found that the prognosis of PB-DLBCL is better than that of SB-DLBCL. What’s more, surgical treatment can improve the prognosis, but the use of Rituximab has no effect on the prognosis.